A study of a GLP-1 medicine, liraglutide, in people with growth hormone deficiency.

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

• 40 healthy subjects, 20 male, 20 female, ages 18-45 yr.: (i) 20 (10 male, 10 female) who are overweight/Class 1 Obese (BMI 25-34.9) with abdominal fat accumulation (central adiposity) defined by waist circumference (WC) ≥ 102 cm in men, ≥ 88 cm in women, except in East/South Asians for whom the criteria will be WC ≥ 90 men and ≥ 80 women; (ii) 20 (10 male,10 female) who are lean (BMI 19-24.9) and not meeting these WC criteria.
• No medical conditions except being overweight/obese in half of subjects
• No prescription medication or other drug use
• On screening testing: BP\<140/\<90 mmHg, HbA1c\<5.7%, FPG\<100 mg/dL, normal IGF-1 and TSH levels.
• Premenopausal women: use of nonhormonal method of contraception

Key exclusion criteria

• History of malignancy, diabetes, thyroid cancer or pancreatitis
• Recent dieting, weight change \>5%, pregnancy or lactation or heavy exercise
• Use of glucocorticoids, hormonal supplements or medications that could affect GH or IGF-1 or for weight loss within 6 months of enrollment
• DM requiring medication
• HbA1C \> 7.5